A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1087-S1087
Number of pages1
JournalJournal of Thoracic Oncology
Volume12
Issue number1
Publication statusPublished - Jan 2017

Cite this